NASDAQ:ICAD - iCAD Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.93 +0.38 (+8.35 %)
(As of 01/21/2019 02:09 AM ET)
Previous Close$4.93
Today's Range$4.57 - $5.05
52-Week Range$2.42 - $4.76
Volume299,842 shs
Average Volume152,733 shs
Market Capitalization$82.69 million
P/E Ratio-8.08
Dividend YieldN/A
Beta0.92
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.

Receive ICAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ICAD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:ICAD
CUSIPN/A
Phone603-882-5200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$28.10 million
Book Value$0.86 per share

Profitability

Net Income$-14,250,000.00

Miscellaneous

Employees119
Market Cap$82.69 million
OptionableOptionable

iCAD (NASDAQ:ICAD) Frequently Asked Questions

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

How were iCAD's earnings last quarter?

iCAD Inc (NASDAQ:ICAD) posted its quarterly earnings results on Tuesday, November, 13th. The technology company reported ($0.06) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.08) by $0.02. The technology company earned $6.19 million during the quarter, compared to the consensus estimate of $6.34 million. iCAD had a negative return on equity of 64.08% and a negative net margin of 37.29%. View iCAD's Earnings History.

When is iCAD's next earnings date?

iCAD is scheduled to release their next quarterly earnings announcement on Thursday, March 28th 2019. View Earnings Estimates for iCAD.

Has iCAD been receiving favorable news coverage?

Media stories about ICAD stock have been trending somewhat negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. iCAD earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned news stories about the technology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.

Who are some of iCAD's key competitors?

Who are iCAD's key executives?

iCAD's management team includes the folowing people:
  • Ms. Stacey M. Stevens, Exec. VP and Chief Strategy & Commercial Officer (Age 51)
  • Mr. Michael S. Klein, Exec. Chairman & CEO (Age 65)
  • Mr. R. Scott Areglado, VP, Corp. Controller & Interim CFO
  • Ms. Annette L. Heroux, VP of Admin. (Age 62)
  • Mr. Jonathan Go, Sr. VP of R&D (Age 56)

How do I buy shares of iCAD?

Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is iCAD's stock price today?

One share of ICAD stock can currently be purchased for approximately $4.93.

How big of a company is iCAD?

iCAD has a market capitalization of $82.69 million and generates $28.10 million in revenue each year. The technology company earns $-14,250,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. iCAD employs 119 workers across the globe.

What is iCAD's official website?

The official website for iCAD is http://www.icadmed.com.

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected]


MarketBeat Community Rating for iCAD (NASDAQ ICAD)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  86 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  184
MarketBeat's community ratings are surveys of what our community members think about iCAD and other stocks. Vote "Outperform" if you believe ICAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel